Mitsubishi UFJ Asset Management Co. Ltd. Purchases Shares of 173,470 Illumina, Inc. $ILMN

Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in shares of Illumina, Inc. (NASDAQ:ILMN) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 173,470 shares of the life sciences company’s stock, valued at approximately $30,501,000. Mitsubishi UFJ Asset Management Co. Ltd. owned about 0.11% of Illumina at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. WCM Investment Management LLC lifted its stake in shares of Illumina by 45.5% in the 1st quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock valued at $715,579,000 after purchasing an additional 1,851,848 shares in the last quarter. Bank of New York Mellon Corp acquired a new position in Illumina during the second quarter valued at approximately $293,846,000. Invesco Ltd. lifted its position in Illumina by 97.0% during the fourth quarter. Invesco Ltd. now owns 2,747,986 shares of the life sciences company’s stock valued at $360,426,000 after buying an additional 1,352,731 shares in the last quarter. AQR Capital Management LLC grew its stake in Illumina by 30.3% during the fourth quarter. AQR Capital Management LLC now owns 4,426,126 shares of the life sciences company’s stock worth $580,531,000 after buying an additional 1,028,099 shares during the period. Finally, Morgan Stanley grew its stake in Illumina by 66.0% during the fourth quarter. Morgan Stanley now owns 2,529,045 shares of the life sciences company’s stock worth $331,710,000 after buying an additional 1,005,474 shares during the period. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Illumina Price Performance

ILMN stock opened at $213.24 on Friday. The company has a quick ratio of 1.40, a current ratio of 1.80 and a debt-to-equity ratio of 0.53. Illumina, Inc. has a 52-week low of $88.00 and a 52-week high of $220.32. The stock’s 50 day moving average is $186.84 and its two-hundred day moving average is $151.97. The company has a market capitalization of $32.20 billion, a PE ratio of 39.78, a P/E/G ratio of 2.89 and a beta of 1.45.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, beating the consensus estimate of $1.23 by $0.08. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The company had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.13 billion. During the same period in the prior year, the business posted $1.19 EPS. The business’s revenue was up 9.4% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Analysts predict that Illumina, Inc. will post 5.36 earnings per share for the current fiscal year.

Insider Transactions at Illumina

In other news, CAO Scott D. Ericksen sold 500 shares of the business’s stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $160.00, for a total value of $80,000.00. Following the completion of the sale, the chief accounting officer owned 14,446 shares of the company’s stock, valued at approximately $2,311,360. The trade was a 3.35% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Scott M. Davies sold 615 shares of the company’s stock in a transaction dated Thursday, July 30th. The shares were sold at an average price of $200.00, for a total transaction of $123,000.00. Following the completion of the sale, the insider owned 20,338 shares in the company, valued at approximately $4,067,600. This trade represents a 2.94% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,416,384 shares of company stock valued at $256,164,151 over the last ninety days. 2.90% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

ILMN has been the topic of a number of research reports. Stifel Nicolaus raised their target price on shares of Illumina from $155.00 to $225.00 and gave the company a “buy” rating in a research note on Friday, July 31st. Barclays upped their price target on shares of Illumina from $145.00 to $160.00 and gave the stock an “underweight” rating in a research report on Friday, July 31st. Deutsche Bank Aktiengesellschaft downgraded Illumina to a “hold” rating in a report on Wednesday, August 5th. Citigroup boosted their price objective on Illumina from $95.00 to $113.00 and gave the stock a “sell” rating in a research note on Monday, August 3rd. Finally, Daiwa Securities Group raised Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 target price for the company in a research report on Thursday, May 14th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $188.40.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.